Teva posts Phase 3 SOLARIS analyses for Medincell

Teva presented new clinical and real-world data at Psych Congress 2026 in New Orleans, supporting durable disease control for its investigational once-monthly olanzapine injectable, olanzapine LAI. FDA action date for olanzapine LAI is expected in Q4 2026; the product remains unapproved.